For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

Intensive blood pressure control in hypertensive chronic kidney disease (CKD) provides a survival advantage and other benefits.

KEEN to lose weight in 2025? So are almost half of our readers. While weight-loss jabs, similar to Ozempic, boomed in ...

BEHIND CLOSED DOORS: A four-hour House Democratic Caucus meeting in Springfield was so contentious that a member of Gov. JB Pritzker ’s team left in tears and the hemp legislation that was at the ...